Germ cell cancer (GCC) is curable in metastatic stages. The International Germ Cell Cancer Collaborative Group (IGCCCG) reports a poor prognosis subgroup with a 5-year survival of 48%. High-dose chemotherapy with PBSC transplantation (HD-PBSCT) in these patients showed promising results in phase II, but failed to show significant advantage in randomized trials. We report our monocenter series of all poor and selected intermediate prognosis germ cell tumor patients treated with multiple-course HD-PBSCT and secondary surgery of remaining tissue. We performed a retrospective analysis of our complete series of 44 patients (40 poor prognosis and 4 intermediate prognosis) treated by HD-PBSCT as part of first-line therapy from 1999 to 2010. The CR rate after up to four cycles of HD-PBSCT and radical resection of residual manifestations was 73%. The 3-year survival rate was 79.5% (median follow-up of 51.5 months; range: 7 --143 months). Disease-related death rate was 16%. HD-PBSCTrelated death did not occur. One patient died postsurgery. Multiple courses of HD-PBSCT with radical secondary surgery is safe and effective in poor prognosis metastatic GCC. Despite disappointing phase III studies it is of high interest to further study this field.
INTRODUCTION
Germ cell cancer (GCC) represents a curable solid tumor entity even in metastatic stages. Based on 5202 GCC cases the International Germ Cell Cancer Collaborative Group (IGCCCG) defined three prognostic subgroups with a survival rate between 48 and 91%. 1 Even though metastatic GCC is potentially curable in the poor prognosis subgroup, 450% of the analyzed patients died. The IGCCCG database reports 14% patients in the poor prognosis subgroup with a 5-year survival rate of 48%. 1 Dose intensification by high-dose chemotherapy with PBSC transplantation (HD-PBSCT) protocols is a therapeutic option in these patients. Phase II results using high-dose (HD) therapy protocols yielded promising results as first-line treatment in poor prognosis patients. 2 In addition, first-line HD-treatment for poor prognosis patients compared favorably with standard therapy by matched pair analysis. 3 The latter study showed an increase of 2-year overall survival by 11% in the HD-PBSCT group of patients. 3 It was disappointing that recently published phase III studies including long-term results failed to show significant advantages of this approach. 4 --6 However, the randomized studies performed thus far have some shortcomings as discussed below and an important subgroup analysis in one of these studies suggests a significant advantage of HD-PBSCT over standard platinum-containing therapy for selected patients. In the subgroup of 67 poor-prognosis patients with unsatisfactory tumor marker decline after induction therapy Motzer et al. 4 reported a 1-year durable response rate of 61% after HD-PBSCT vs 34% (P ¼ 0.04) after standard therapy and a trend towards an increased 2-year survival. The recently published EORTC 30974 trial, however, performed a subgroup analysis which did not demonstrate an influence of tumor marker decline. 5 In this report we present our retrospective single center experience including all poor and intermediate prognosis germ cell tumors (GCT) patients referred to us. In view of the unsatisfactory results with standard chemotherapy for poor prognosis CGT patients, 1 our initial good experience within a dose-escalation phase I/II trial of the German Testicular Cancer Study Group 2 and the published data on a matched pair analysis, 3 our center decided to treat these patients with a sequence of individually tailored, multiple standard and HD chemotherapy cycles followed by secondary surgery of remaining manifestations and/or radiation of the brain and bone metastasis. We did not consider the data published in the randomized trials thus far convincing enough to change this treatment strategy. Further, the IGCCCG does not provide the category poor prognosis for seminoma patients, 1 however, Fossa et al. 7 published a prognostic score based on data from 286 patients with advanced seminoma showing a 3-year PFS of 56% for patients with visceral metastasis other than to the lungs only and lactate deydrogenase (LDH) elevation. In addition, Moran et al. 8 characterized 120 cases of primary mediastinal seminomas and reported a survival of B50% for the patients older than 37 years. As the outcome for these 'intermediate' prognosis seminoma patients is bad, we decided to include three seminoma patients with a high risk according to these clinical features into our HD therapy algorithm. We report on a CR rate after HD-PBSCT and resection of residual GCT manifestations of 73%, a 3-year survival rate of 79.5% with a median follow-up of 51.5 month (range: 7 --143 months), a disease-related death rate of 16% without any treatment-related death after HD-PBSCT and one patient dying postsurgery.
PATIENTS AND METHODS Patients
In all, 44 patients (40 poor prognosis; 4 intermediate prognosis according to IGCCCG) with newly diagnosed GCC were referred to our institution between 1999 and 2010 and received HD-PBSCT. All of the poor prognosis patients suffered from non-seminomatous GCT. Three out of the four intermediate prognosis patients suffered from advanced seminoma with clinical high-risk features. The median age of all 44 patients was 30 years (range 17 --62 years). Baseline evaluation included an abdominal, thoracic and cerebral computed tomography (CT), bone scan and measurements for alpha-fetoprotein (AFP), b-human chorionic gonadotropin (beta-HCG) and lactate dehydrogenase (LDH). Comorbidity preventing HD-PBSCT was excluded by creatinine clearance, echocardiography, lung functional testing including diffusion capacity and audiometry. Informed consent was obligatory for every patient before starting the treatment sequence. Acute or chronic infectious diseases were excluded before onset of therapy. There were no exclusions of patients because of these investigations and all patients referred to us were treated and evaluated in this report. All patients were offered the possibility to cryopreserve sperm. The patient's characteristics are depicted in Table 1 .
Treatment protocol
Before HD-PBSCT all patients received at least one cycle and up to six cycles of standard-dose cisplatin-etoposide-ifosfamide (PEI) chemotherapy (Table 2 ). Doses were adapted from the previous experience in a large phase I/II trial 2 with a slightly higher etoposide dose (Table 2 ). PEI was followed by granulocyte-colony stimulating factor for stem cell mobilization. Upon measuring 410 CD34 þ mononuclear cells per mL in the peripheral blood, stem cell harvest was performed by standard peripheral blood leukapheresis. Further stem cell processing and cryoconservation was conducted according to GMP guidelines. A minimum collection of 4 Â 10 6 CD34 þ mononuclear cells per kg body weight was required for one cycle of HD therapy. The number of standard dose PEI cycles was increased whenever the number of CD34 þ mononuclear cells collected was too low, if fever occurred during stem cell collection, or if application of HD chemotherapy at the time was assessed unsafe by the treating physician because of clinical condition of the patient. The applicated HD chemotherapy regimen HD-PEI was adapted from our previous experience in a large phase I/II trial (dose level 6). 2 In 14 patients we added paclitaxel according to dose level 3 of the phase I/II study by the German Testicular Cancer Study Group. 9 Up to four cycles of HD-chemotherapy were administered according to individual patient's response and tolerability. Number of HD cycles were determined for individual patients according to the quality of their response and the tolerability of previous cycles. It was the objective to give the last cycle of HD-therapy upon marker normalization induced by previous therapy cycles. For SCT we preferentially used preparations harvested after more than one PEI cycle to exploit potential in vivo purging effects of the chemotherapy. Patients with residual disease in CT or positron-emission tomography-CT underwent secondary surgery whenever technically feasible. Table 2 summarizes the number of cycles of induction chemotherapy and HD-chemotherapy administered and the dosing schedules. Intensive supportive care after PEI and HD therapy included granulocyte-colony stimulating factor, prophylactic antibiotics, antiemetics, liberal platelet and red blood cell transfusions. In-house observation of the patients after HD therapy until recovery of cellular blood counts was obligatory. Intervention antibiotic therapy for fever 438 1C consisted of a double regimen with tazobactam/piperacillin plus aminoglycoside with obligatory switch to either sensitivity-targeted antibiotics or to carbapenem plus vancomycin plus systemic antifungal drugs after 72 h with ongoing temperatures X38 1C.
Assessment of response and and long-term outcome
Radiographic reevaluation by CT-scans or in some patients positronemission tomography-CT was performed B4 weeks after each HD-PBSCT. Tumor marker analysis was routinely repeated after each course of therapy High-dose therapy in poor prognosis germ cell cancer M Mohr et al and B4 weeks after each HD-PBSCT. Complete response (CR) was defined as disappearance of all radiographic evidence of remaining disease and tumor marker normalization after HD-PBSCT. Partial response (PR) was defined as radiographic evidence of response without disappearance of the disease. This group was divided in marker-negative and markerpositive PR. CR after surgery was defined as disappearance of all radiographic evidence of remaining disease and tumor marker normalization after HD-PBSCT and resection of all residual disease, if viable GCT was found in the resected tissue. If resected masses contained mature teratoma or necrotic debris the response was classified as CR to chemotherapy according to Motzer et al. 4 Event Free Survival was defined by the time interval between treatment onset and either disease progression/treatment failure, relapse or death from any cause for all patients. Long-term survivors were contacted at the time of writing this report (Februrary 2011) to update actual disease status. Overall Survival was defined by the time interval between treatment onset and death from any cause for all patients. Kaplan --Meier survival analysis was performed by using Statistical Package for Social Science software (SPSS) version 17.0.
RESULTS
We evaluated patient's characteristics, response rate and followup data of the complete series of 44 poor and intermediate prognosis GCC patients, treated in our institution between 1999 and 2010 with HD-PBSCT. HD-PBSCT led to a CR rate of 50%. In all, 16 (36%) were evaluated as PR, with 8 of those obtaining a tumor marker positive PR. Six (14%) of the patients were refractory to therapy. In 26 patients (59%) resection of residual disease was performed. These 26 patients also comprised PR cases, who had no viable tumor in the resection material. Therefore they were reclassified as CR after HD-PBSCT, and thus are part of the HD-PBSCT CR rate of 50% as stated above. In four cases of those (15% of the operated patients) viable GCT was detected, six cases (23% of the operated patients) showed mature teratoma. HD-PBSCT and resection of residual tumor manifestations resulted in a CR rate of 73% (50% for intermediate prognosis patients and 75% for poor prognosis patients). As it became available we used positronemission tomography-CT after the last HD-PBSCT cycle for prioritizing sequential surgery targets in patients who had remaining tissue in both the thorax and abdomen. Three patients who showed a marker-negative PR did not undergo surgery, because they were positron-emission tomography negative and/ or fine needle aspiration did not show viable tumor. In none of these cases progressive disease occurred in later follow-ups, however, according to Motzer et al. 4 these patients were not classified as CR.
After a median follow-up of 51.5 months six patients had died from progressive disease and one patient after relapse. One patient, who achieved PR died during treatment of secondary malignancy (CML). One patient died from perioperative ischemic stroke after pulmonal resection of residual disease (mature teratoma). This resulted in a 3-year overall survival of 79.5% (75% in the intermediate prognosis group and 80% in the poor prognosis group). The 3-year event free survival was 72.5% (75% in the intermediate prognosis group and 72.5% in the poor prognosis group) (Supplementary Table 1 ; Figures 1a-d) .
Three patients who relapsed after HD-PBSCT are alive. One of those patients relapsed 10 years after HD-PBSCT and salvage therapy (PEB) is currently ongoing. Two relapsed patients are in CR after salvage therapy and resection or irradiation of recurrent disease. The disease related death rate was 16% (0% for intermediate prognosis patients and 18% for poor prognosis patients) (Supplementary Table 1 ). All three patients with advanced seminoma included in this series for clinical high-risk features are alive and disease free.
In 14 patients we added paclitaxel to HD-chemotherapy. 9 Retrospective analysis of this subgroup revealed results comparable to the total group with CR rate after up to four cycles of HD-PBSCT and radical resection of residual manifestations being 71.5% and 3-year survival rate being 71.5%. However, patient numbers are too small for meaningful statistical comparison of both HD-protocols. Eight patients with marker-positive PR received resection of residual disease. In none of these cases did histology show viable tumor, however, marker-decline occurred postoperatively. One of these patients received salvage therapy before resection. Two relapses occurred (10 and 23 months from treatment start) with one patient achieving a second CR after resection of pulmonary metastasis and remaining in CR after 97 months of follow-up. The other patient died from progressive disease after salvage therapy (oxaliplatin/gemcitabine). Thus, seven out of eight patients with surgery upon marker-positive PR are alive and disease free.
Seven patients suffering from brain metastasis underwent additional surgery whenever possible and radiation therapy. Four patients out of these seven are alive and three died from progressive disease.
Data on hematopoietic recovery and toxicity concerning neutropenic fever and respirator episodes on an intensive care unit are depicted in Supplementary Table 1 . Other nonhematopoietic toxicity with the regimen used did not exceed grade 3 (WHO scale), with peripheral neuropathy and/or hearing loss X grade 2 occurring in the majority of patients.
DISCUSSION
Our retrospective report on a monocenter series of 44 patients with poor (n ¼ 40) and intermediate (n ¼ 4) prognosis GCT patients shows, that an approach using individually tailored, multiple cycles of HD-PBSCT with intensive supportive care and in-house observation plus subsequent radical surgery of remaining tumor tissue is safe and effective. We have observed highremission rates and only one death after secondary surgery, resulting in a 79.5% survival rate at 3 years follow-up for all 44 patients. However, there is higher evidence from randomized trials showing no role of HD-PBSCT in poor prognosis GCT patients. Yet, these trials have some shortcomings.
Motzer et al. 4 have reported the results of a randomized phase III trial comparing HD-PBSCT with standard dose cisplatinetoposide-bleomycin (PEB) in 219 cases. This trial did not show a significant advantage for the HD-PBSCT group with a 2-year survival of 71% vs 72% in the standard treatment group. However, subgroup analysis showed a significant advantage for HD-PBSCT in patients with unsatisfactory tumor marker decline during induction chemotherapy with a better 1-year durable CR rate (61% vs 34%; P ¼ 0.04) and a trend towards superior 2-year overall survival (78% vs 55%; P ¼ 0.11). After HD-PBSCT the 2-year overall survival of patients with unsatisfactory marker decline did not differ from the patients with satisfactory decline (78% vs 78%). The significant advantage of HD-PBSCT in the patient group with unsatisfactory marker decline was caused by the inferior results of the patients in the standard therapy arm. Toxic death, however, occurred in 6.9% of the patients in the HD therapy group, which in comparison to our data is very high and complicates the interpretation of the final results of this study.
Recently, the results of the EORTC 30974 trial have been published. 5 Overall, 131 patients had been randomized to receive standard bleomycin, etoposide, cisplatin (BEP) or one cycle PEI followed by HD-PBSCT. The trial was closed prematurely by the data monitoring committee because of slow recruitment. The failure-free survival rate was significantly improved (18.1%) by HD-PBSCT after 1 year (48% after BEP vs 66.1% after HD-PBSCT; P ¼ 0.035), but not after 2 years (44.8% after BEP, 58.2% after HD-PBSCT; P ¼ 0.06). There was no difference in the overall survival. In contrast to Motzer et al. 5 subgroup analysis did not show an advantage for HD-PBSCT in patients with unsatisfactory tumor marker decline. Also in this trial there was excess toxic death of the HD therapy of 3.1% vs 1.5% in the BEP group. This and the premature closure of this trial with a small number of patients included renders the results of this trial difficult to interpret.
Droz et al. 6 presented long-term results of an early randomized trial, which failed to demonstrate a benefit of HD chemotherapy in mainly intermediate and poor prognosis non-seminomatous GCT after a median follow-up of 9.7 years. In a subgroup analysis there was even a significant decrease of overall survival upon HD therapy in the poor prognosis subgroup. As this trial was performed in the pre-PBSCT-time between 1988 and 1991 the stem cell support was performed by autologous BM. This and the suboptimal therapy in the HD group may have resulted in the high toxic and early-death rate in the HD-group (3.5% toxic deaths and further 10.5% early deaths in the HD group vs 1.75% in the control group). 6 In addition, only one HD chemotherapy cycle was administered.
The fourth trial on HD-PBSCT in poor prognosis GCT until now has been only reported in abstract form. 10 It reports randomization of a small number of 89 patients between 4 Â PEB vs 2 Â PEB followed by a sequence of four HD cycles with different drugs followed by autologous stem cells. The authors stopped the trial prematurely because of prolonged accrual time and the results of an interim analysis and report a OS difference of 66.8% (HD) vs 60.5% (PEB) as not being significant. Further detailed publication of the results must be awaited.
The results of our retrospective analysis yields results similar to the published matched-pairs analysis 2 and compare favorably with the results of the EORTC 30974 trial 5 and the results presented by Motzer et al. 4 The CR rate was 73% after HD-PBSCT and resection of residual disease. With a median follow-up of 51.5 months, survival after 3 years was 79.5% for all patients and 80% for the 40 patients with poor prognosis. In the 44 patients no toxic death related to the HD regimen occurred, and only one early death occurred because of disease progression between the HD cycles (2%). In the 73% patients who achieved CR after HD-PBSCT and resection of residual disease, only one late relapse (after 10 years) occurred. Possible reasons for these comparatively favorable results are not based on selection of our patient group, as every single patient referred to us was treated and there were no exclusions from evaluation in our series reported here. However, in contrast to other groups we administered a variable number PEI induction cycles and more than one cycle of HD-PBSCT with unrestricted supportive care and in-house observation until recovery of cellular blood counts. Close response and toxicity monitoring allowed for an individual tailoring of the number of HD-PBSCT cycles with 30 out of 44 patients receiving three and further 7 out of 44 patients receiving four HD-PBSCT cycles. Further, an aggressive approach for secondary surgery early after systemic treatment rendered additional 10 patients (23%) disease free with an acceptable death rate and good long-term outcome. This was not the study objective in the randomized trials, however, some of them reported on only few patients undergoing secondary surgery after chemotherapy. 6 In our series, one patient with non seminomatous GCC with IGCCCG intermediate risk died after surgery from perioperative ischemic stroke, a complication which may also have occurred after standard PEB therapy.
Our series, like the randomized trial reported by Motzer et al.,
no disease-related death occurred. This observation and the fact that salvage therapy including high-dose protocols of relapsing or refractory disease yields survival rates of only B50%, 12 should be considered when treatment decisions are made for individual patients.
In summary, multiple cycles of induction PEI chemotherapy, followed by sequential HD-PBSCT under active supportive care and an aggressive secondary surgery approach is a safe and effective therapeutic strategy for poor prognosis GCT patients. The impact of HD-PBSCT on the prognosis of these patients, however, is still not clear. In the subgroup analysis reported by Motzer et al. 4 the negative impact of unsatisfactory tumor marker decline may be compensated by HD-PBSCT. In clinical practice the treatment decision regarding HD-PBSCT should be individualized, for example, implicating the tumor marker decline after induction therapy. Further definitive phase III studies in this field with acceptable toxicity data and patient numbers allowing final conclusions are highly desirable.
